新生儿脑损伤生物学标志物研究进展  

Study progress of biomarkers in neonatal brain injury

作　　者：邱洁[1] 

机构地区：[1]南京医科大学附属儿童医院新生儿医疗中心,210008

出　　处：《中华实用儿科临床杂志》2017年第2期91-95,共5页Chinese Journal of Applied Clinical Pediatrics

摘　　要：过去几十年，生物学标志物作为无创工具在很多疾病的早期诊断及监测中被广泛应用。在围生医学，随着高危新生儿的存活率增高，越来越迫切需要可监测新生儿脑损伤的生物学标志物应用于临床。因为新生儿脑损伤的临床表现较为隐匿，当临床表现和监测参数发生变化时往往已错过最佳治疗时机，所以早期发现脑损伤的高危新生儿非常关键。这些生物学标志物的应用可使临床医师在疾病的早期即进行干预，并监测这些干预的有效性。然而，目前尚无足够充分的研究保证这些标志物常规应用于临床。现总结目前研究较多的生物学标志物，如激活素A、S100B蛋白、胶质纤维酸性蛋白、肾上腺髓质素、神经特异性烯醇化酶、白细胞介素-6、转化生长因子-β、尿酸、有核红细胞、血红素氧化酶-1在监测新生儿脑损伤中的作用。Over the past few decades,biomarkers have become increasingly utilized as non - invasive tools in the early diagnosis and management of various clinical conditions. In perinatal medicine, the improved survival of infants who are at high risk for adverse neurologic outcomes has increased the demand for the discovery of biomarkers in detec- ting and predicting the prognosis of in term and preterm newborns with neonatal brain injury. Recognization potential brain damage early is crucial because clinical feature and monitoring parameters may be of no avail and therapeutic win- dow for pharmacological intervention is very limited. Therefore, the measurement of biochemical markers of brain damage is eagerly awaited in clinical practice to detect high risk infants. These biomarkers could allow clinicians to in- tervene at the early stages of disease, and to monitor the efficacy of those interventions. None, however, were studied ex- tensively enough to warrant routine clinical use. The present paper is aimed at investigating the role of the main biomar- kers such as activing A, S100B, glial fibrillary acidic protein, adrenomedullin, neuron - specific enolase, interleukin - 6, hemeoxygenase - 1, transforming growth factor β, uric acid, nucleated red blood ceils, currently studied in infants with neonatal brain injury.

关 键 词：围生期窒息 婴儿 新生 脑损伤 生物学标志物 激活素A SIOOB蛋白 

分 类 号：R742[医药卫生—神经病学与精神病学]